Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-01-19-Speech-3-380-500"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2011-01-19"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"pt"^^xsd:language2
lpv:document identification number	"en.20110119.20.3-380-500"2
lpv:hasSubsequent	lp_eu:2011-01-19-Speech-3-381-0002
lpv:speaker	lp:José Manuel Fernandes2
lpv:spokenAs	substitute; Delegation to the ACP-EU Joint Parliamentary Assembly (2010-03-05--2014-06-30)3 member; BUDG (2009-07-16--2012-01-18)3 substitute; Delegation for relations with India (2009-09-16--2014-06-30)3 member; Delegation for relations with the People's Republic of China (2009-09-16--2014-06-30)3 substitute; ENVI (2009-07-16--2012-01-18)3 member; Special committee on the policy challenges and budgetary resources for a sustainable European Union after 2013 (2010-06-17--2011-06-30)3 member; EPP (2009-07-14--2014-06-30)3 unknown; Partido Social Democrata (2009-07-14--2014-06-30)3
lpv:translated text	"The issue under discussion is an inhaler for asthma that has been on the market since 1996. The German authorities expressed concerns about this product and informed the Commission with a view to launching and concluding a safeguard procedure. However, the Commission did not consult the manufacturer and never issued a ruling, so a decision on the matter is still pending and the petitioner is left without any available means of legal redress. The manufacturer placed the device on the market under a new name in 2003 and, in 2005, the government of Upper Bavaria ordered it to be withdrawn from the market, under the German Medical Devices Act, without informing the Commission accordingly. The manufacturer informed the Commission of the second sales prohibition with a view to initiating infringement proceedings against Germany, but the Commission claims that there was insufficient proof that the inhaler satisfied the essential requirements stipulated in the directive, and it concluded that there was no need for a new product safety review. I voted in favour of this resolution because I believe it to be imperative that the Commission urgently respond to the legitimate concerns of the injured party, to enable him to assert his rights."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph